WHO Discontinues Hydroxychloroquine And HIV Drug Trials For COVID-19 Patients

On Saturday, the World Health Organisation announced the discontinuation of hydroxychloroquine and lopanavir/ritonavir trials for treatment of COVID-19 patients, on recommendation from the Solidarity Trial’s International Steering Committee.

"The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation", WHO stated in a press release.

As per WHO, the interim trials results from the above drugs produced "little or no reduction in the mortality of hospitalised COVID-19 patients" as compared to standard of care. These results are currently being prepared for peer-reviewed publication.